Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6780534 | 0.83 | KMT2A (0.54) | CRHR1MEN1KMT2AHTTNPSR1 | |
| SCHEMBL6775008 | 0.76 | CRHR1 (0.47) | CRHR1MEN1KMT2ANPSR1MAPT | |
| SCHEMBL6770041 | 0.76 | CRHR1 (0.46) | CRHR1MEN1KMT2APIK3CBPOLB | |
| SCHEMBL6774484 | 0.74 | CRHR1 (0.45) | CRHR1MEN1KMT2AHTTNPSR1 | |
| SCHEMBL6770527 | 0.74 | CRHR1 (0.45) | CRHR1MEN1KMT2ANPSR1MAPT | |
| SCHEMBL13029832 | 0.74 | MAPK1 (0.65) | CRHR1MEN1KMT2AHTTNPSR1 | |
| SCHEMBL6885335 | 0.73 | POLB (0.46) | MEN1KMT2AHTTNPSR1MAPT | |
| SCHEMBL7680790 | 0.70 | CRHR1 (0.88) | CRHR1MEN1KMT2ANPSR1MAPT | |
| SCHEMBL7011083 | 0.70 | MAPT (0.50) | MEN1KMT2AHTTNPSR1MAPT | |
| SCHEMBL14146780 | 0.68 | POLB (0.46) | CRHR1MEN1KMT2AHTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030191125-A1 | Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-10-09 | — | — | US | claimed |
| US-20020040026-A1 | Aryloxy-and arylthiosubstituted pyrimidines and triazines and derivatives thereof | DUPONT PHARMACEUTICALS COMPANY | 2002-04-04 | — | — | US | claimed |
| US-6326368-B1 | PSYCHOLOGICAL DISORDERS | DUPONT PHARMACEUTICALS COMPANY | 2001-12-04 | — | — | US | claimed |
| US-6818648-B2 | PSYCHOLOGICAL DISORDERS; ANXIOLYTIC AGENTS; ANTIDEPRESSANTS; EATING DISORDERS; ALCOHOLISM; DRUG ABUSE; ANTIINFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB PHARMA | 2004-11-16 | — | — | US | disclosed |
| US-20030191125-A1 | Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-10-09 | — | — | US | disclosed |
| US-20020040026-A1 | Aryloxy-and arylthiosubstituted pyrimidines and triazines and derivatives thereof | DUPONT PHARMACEUTICALS COMPANY | 2002-04-04 | — | — | US | disclosed |
| US-6326368-B1 | PSYCHOLOGICAL DISORDERS | DUPONT PHARMACEUTICALS COMPANY | 2001-12-04 | — | — | US | disclosed |
| EP-0920318-A4 | ARYLOXY- AND ARYLTHIOSUBSTITUTED PYRIMIDINES AND TRIAZINES AND DERIVATIVES THEREOF | DU PONT PHARM CO (US) | 2000-03-15 | — | — | EP | disclosed |
| EP-0920318-A1 | ARYLOXY- AND ARYLTHIOSUBSTITUTED PYRIMIDINES AND TRIAZINES AND DERIVATIVES THEREOF | Du Pont Pharmaceuticals Company (US) | 1999-06-09 | — | — | EP | disclosed |
| WO-1997035580-A1 | ARYLOXY- AND ARYLTHIOSUBSTITUTED PYRIMIDINES AND TRIAZINES AND DERIVATIVES THEREOF | DU PONT PHARMACEUTICALS COMPANY (US) | 1997-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191125-A1 | Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof | PARL, HTR5A, PSEN2 | CRHR1 51/4885MEN1 3005/4885KMT2A 3678/4885 |
| US-20020040026-A1 | Aryloxy-and arylthiosubstituted pyrimidines and triazines and derivatives thereof | PARL, HTR5A, PSEN2 | CRHR1 53/4885MEN1 2942/4885KMT2A 3659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.